AlkyonTx

Alkyon Therapeutics, Inc. (referred to as AlkyonTx™), established in 2024, is an innovative biotechnology company based in San Diego, USA, focusing on developing next-generation radioligand therapy (RLT) aimed at addressing the treatment challenges of refractory solid tumors. The company leverages its proprietary technology platform to deeply analyze the complex mechanisms of the tumor microenvironment (especially the extracellular matrix ECM and stroma), identifying novel therapeutic targets with high translational potential. Based on engineered antibody structures and innovative radiolabeling conjugation technology, Alkyon effectively overcomes bottlenecks such as poor penetration and drug resistance faced by traditional RLT in solid tumor treatments. Currently, through strategic collaborations with partners like Nanobio (utilizing the Harbour Mice® platform for targeted therapy development), the company is accelerating the clinical translation of breakthrough therapies, bringing a new technological paradigm to the field of precision radiotherapy for cancer.